3',4'-Methylenedioxy-α-pyrrolidinobutyrophenone (MDPBP) is a stimulant of the cathinone class developed in the 1960s,[1][2] which has been reported as a novel designer drug.[3][4] MDPBP is sometimes sold under the name "NRG-1" as a mixture with other cathinone derivatives, including flephedrone, pentylone, MαPPP and its higher homologue MDPV.[5] As with other cathinones, MDPBP has been shown to have reinforcing effects in rats.[6]
The main metabolic steps are thought to be demethylenation followed by methylation of one hydroxy group, aromatic and side chain hydroxylation, oxidation of the pyrrolidine ring to the corresponding lactam as well as ring opening to the corresponding carboxylic acid. CYP2C19 and CYP2D6 have been identified as the isoenzymes mainly responsible for demethylenation.[7]
Legal Status
As of October 2015[update] MDPBP is a controlled substance in Poland and China.[8]
^DE 1545591, Koeppe H, Zeile K, Ludwig G, "Verfahren zur Herstellung von α-Aminoketonen mit heterocyclischer Aminogruppe", published 28 May 1965, issued 7 August 1969, assigned to Boehringer Ingelheim
^Westphal F, Junge T, Klein B, Fritschi G, Girreser U (June 2011). "Spectroscopic characterization of 3,4-methylenedioxypyrrolidinobutyrophenone: a new designer drug with α-pyrrolidinophenone structure". Forensic Science International. 209 (1–3): 126–32. doi:10.1016/j.forsciint.2011.01.016. PMID21316166.
^Meyer MR, Mauer S, Meyer GM, Dinger J, Klein B, Westphal F, Maurer HH (July–August 2014). "The in vivo and in vitro metabolism and the detectability in urine of 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MS(n.)". Drug Testing and Analysis. 6 (7–8): 746–56. doi:10.1002/dta.1559. PMID24124065.
^"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.